Mind-altering substances could be on the cusp of medical acceptability, with sovereign wealth funds Temasek and Mubadala in talks to fund biotech groups harnessing their potential
As part of the renewed interest in the potential health applications of psychedelics in recent years, companies ranging from biotechnology startups to.
Dr. Hans Eriksson, chief clinical development officer at HMNC Brain Health, discusses the ways AI-driven precision psychiatry can be leveraged to target the use of medications and improve patient outcomes.
Mass General to conduct research on how psychedelics affect the brain
The hospital is collaborating with a German company and has launched a center to study hallucinogens.
By Anissa Gardizy Globe Correspondent,Updated January 27, 2021, 9:56 a.m.
Email to a Friend
Massachusetts General Hospital is working with German company atai Life Sciences to study how psychedelics affect the brain.Josh Reynolds/The Washington Post
Massachusetts General Hospital is working with a German company to research the effects of psychedelics on the brain.
Atai Life Sciences
â which on Tuesday
jointly announced the collaboration with Mass General â acts like an incubator for psychedelic therapy-focused companies, acquiring majority stakes in small biotechs and launching its own startups.